About Novartis AGNovartis is located in East Hanover, New Jersey, Novartis Pharmaceuticals Corporation is an affiliate of Novartis AG, which provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care and cost-saving generic pharmaceuticals. Novartis is the only global company with leading positions in these areas. In 2015, the Group achieved net sales of USD 49.4 billion, while R&D throughout the Group amounted to approximately USD 8.9 billion (USD 8.7 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 118,000 full-time-equivalent associates. Novartis products are available in more than 180 countries around the world.
For more information, visit www.novartis.com and follow us on www.twitter.com/Novartis
CEO: Joseph Jimenez
CMO: Vasant (Vas) Narasimhan
CFO: Harry Kirsch
Please click here for Novartis job opportunities.
Please click here for clinical trial information.
FOLLOW NOVARTIS: Tweets by Novartis
1398 articles with Novartis AG
AbbVie’s Humira is the world’s best-selling drug that generated more than $18 billion for the Illinois-based company last year. This week though, the company will begin to see challenges to Humira in Europe from biosimilars developed by Amgen and Novartis, as well as others.
Again and again … and again, drugs have failed in clinical trials for Alzheimer’s disease. According to a new report, in the last decade, 146 drugs have failed in clinical trials for Alzheimer’s.
Allogene Therapeutics began trading on the Nasdaq Stock Exchange today under the ALLO ticker. The price was at the top of its range, $18 per share. The company plans to raise $288 million with the sale of about 16 million shares.
Genentech, a Roche company, released data from a long-term clinical trial of Ocrevus in multiple sclerosis. Meanwhile, Novartis isn’t standing still on MS. Earlier this week the company announced that both the FDA and EMA had accepted its NDA and MAA, respectively, for siponimod.
10/10/2018A post-hoc analysis of a Phase II sickle cell disease study showed that patients treated with crizanlizumab significantly reduced occurrences of vaso-occlusive crisis, a serious disease complication that can lead to organ failure.
The AP in a recent report notes that drug price increases “slowed somewhat and were not quite as steep as in past years.” But overall, there has been no “massive” drug price cuts.
Celgene Corporation presented data at the 34th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis (ECTRIMS) held in Berlin, Germany with results from two Phase III trials.
To spur innovation and bolster ties with tech giants, Swiss pharma giant Novartis plans to set up innovation labs across the globe to partner with these companies to spur the development of new therapies.
10/9/2018Bristol-Myers Squibb, Nektar Therapeutics, Amgen and others will be recognized for their significant contributions to the California life sciences industry during the November 2018 Pantheon DiNA Awards hosted by the California Life Sciences Association.
A study published in the Annals of Internal Medicine highlights some of the problems that drug shortages bring to the healthcare system, including a rise in prices. The research, as highlighted by Business Insider, examined the prices of 917 drugs that were in shortage between 2015 and 2016.
Swiss pharma giant Novartis could be on its way to securing regulatory approval for its secondary progressive multiple sclerosis (SPMS) treatment siponimod.
10/4/2018As cancers develop treatment resistance, combinations of old and new therapies will become increasingly important to effective treatment. The use of multiple, potentially costly, drugs during combination therapy, increased duration of novel therapies and the possibility of patients needing multip...
Technology has had a massive impact on basically every area of life. One very important part of medical research that technology has been having a noticeable impact on is clinical trials.
Immuno-oncology comes pretty close to being a miracle cure for certain types of cancer. But it's not perfect, and a recently reported isolated case demonstrates that there are risks.
Boston Pharma went on a buying binge, licensing a slew of compounds from GlaxoSmithKline and Novartis in two separate deals.
10/2/2018Janssen Biotech, a Johnson & Johnson company, informed Aduro Biotech that it was terminating its research and license deals related to Aduro’s Listeria treatment for cancers.
Thomson Reuters recently announced their list of the top 100 most diverse and inclusive organizations. In the top 50 of the list there are 10 biopharma and medical device companies. Let’s take a look.
Swiss-based Roche announced it is buying UK-based Tusk Therapeutics in a deal that could hit $758 million (U.S.).
The U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s Emgality (galcanezumab-gnlm) for migraine prevention.
Cellular Biomedicine Group Enters Into Strategic Licensing and Collaboration Agreement with a Global Leader in CAR-T Cell Therapy for Patients in China
Cellular Biomedicine Group Inc. (NASDAQ: CBMG) today announced it has entered into a strategic licensing and collaboration agreement with Novartis to manufacture and supply the CAR-T cell therapy Kymriah® (tisagenlecleucel) in China. Novartis will be the exclusive holder of the marketing license.